We are live on ! Find out more
NVS icon

Novartis

904 hedge funds and large institutions have $18.3B invested in Novartis in 2016 Q4 according to their latest regulatory filings, with 121 funds opening new positions, 302 increasing their positions, 354 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more first-time investments, than exits

New positions opened: 121 | Existing positions closed: 80

21% more call options, than puts

Call options by funds: $98.8M | Put options by funds: $81.4M

3% more funds holding

Funds holding: 877904 (+27)

0.62% more ownership

Funds ownership: 10.03%10.65% (+0.62%)

2% less capital invested

Capital invested by funds: $18.7B → $18.3B (-$411M)

15% less repeat investments, than reductions

Existing positions increased: 302 | Existing positions reduced: 354

25% less funds holding in top 10

Funds holding in top 10: 2821 (-7)

Holders
904
Holders Change
+27
Holders Change %
+3.08%
% of All Funds
22.6%
Holding in Top 10
21
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-25%
% of All Funds
0.53%
New
121
Increased
302
Reduced
354
Closed
80
Calls
$98.8M
Puts
$81.4M
Net Calls
+$17.4M
Net Calls Change
+$12.4M
Name Holding Trade Value Shares
Change
Change in
Stake
AL
451
Aspiriant LLC
California
$1.01M +$44.1K +680 +5%
RG
452
Rikoon Group
New Mexico
$1M +$115K +1,777 +14%
PAM
453
Palisade Asset Management
Minnesota
$999K
FFC
454
First Financial Corp
Indiana
$994K +$54.2K +835 +6%
SCM
455
Shelton Capital Management
Colorado
$992K
CPIM
456
Columbia Partners Investment Management
Virginia
$987K -$21.4K -330 -2%
RFA
457
Reilly Financial Advisors
California
$982K +$91.3K +1,407 +10%
OC
458
Oarsman Capital
Wisconsin
$977K -$175K -2,701 -15%
RGC
459
Roberts, Glore & Co
Illinois
$972K +$25.3K +390 +3%
CCA
460
Checchi Capital Advisers
California
$964K -$125K -1,921 -12%
SG
461
StoneX Group
New York
$963K +$957K +14,747 New
ST
462
Somerset Trust
Pennsylvania
$953K -$45.3K -698 -5%
CTC
463
Central Trust Company
Missouri
$950K +$13.6K +210 +1%
FMC
464
First Merchants Corp
Indiana
$947K -$50.4K -777 -5%
TH
465
Timber Hill
Connecticut
$947K +$10.7K +165 +1%
BMO
466
Beck Mack & Oliver
New York
$942K -$253K -3,906 -21%
First Eagle Investment Management
467
First Eagle Investment Management
New York
$936K
Bessemer Group
468
Bessemer Group
New Jersey
$936K +$90.7K +1,398 +11%
CG
469
Caprock Group
Idaho
$923K -$874K -13,473 -49%
MCM
470
Murphy Capital Management
New Jersey
$923K +$36.2K +558 +4%
WCBA
471
Weaver C. Barksdale & Associates
Tennessee
$922K +$316K +4,868 +53%
CIC
472
Carnegie Investment Counsel
Ohio
$914K +$7.26K +112 +0.8%
SRP
473
Saddle Road Partners
Nebraska
$910K
SCM
474
Salem Capital Management
Massachusetts
$905K -$187K -2,890 -17%
JFA
475
JNBA Financial Advisors
Minnesota
$905K +$517K +7,970 +135%

NVS Hedge Fund Activity: Q4 2016 in Review

904 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2016, worth a combined $18.3B — down 2.2% from $18.7B a quarter earlier.

Buyers outnumbered sellers: 121 funds opened new NVS positions and 80 closed out — a net gain of 41 holders — while 302 added to existing stakes and 354 trimmed.

The largest buyer was 1832 Asset Management, adding an estimated $213M. The largest seller was Cambiar Investors, exiting entirely with an estimated $176M sold.

  • 904 institutional investors held Novartis (NVS) as of Q4 2016, up from 877 in Q3 2016.
  • Funds reported $18.3B of Novartis stock for Q4 2016, down 2.2% quarter-over-quarter.
  • 121 funds opened new Novartis positions in Q4 2016 and 80 closed out, a net change of +41 holders.
  • The largest Novartis buyer in Q4 2016 was 1832 Asset Management, an estimated $213M added.
  • The largest Novartis seller in Q4 2016 was Cambiar Investors, an estimated $176M sold.

Based on aggregated 13F filings for Q4 2016.